Stockscreener 앱 받기
517.26
0.71%
3.67
시간 외 거래:
517.67
0.41
+0.08%
전일 마감가:
$513.59
열려 있는:
$513
하루 거래량:
160.79K
Relative Volume:
0.47
시가총액:
$11.93B
수익:
$1.13B
순이익/손실:
$-309.44M
주가수익비율:
-40.41
EPS:
-12.8001
순현금흐름:
$-275.41M
1주 성능:
-1.23%
1개월 성능:
-2.25%
6개월 성능:
-5.60%
1년 성능:
+89.23%
1일 변동 폭
$507.06
$520.89
1주일 범위
$499.34
$528.99
52주 변동 폭
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
517.26 | 11.84B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-06 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-02-28 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 개시 | BofA Securities | Underperform |
| 2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 재확인 | Oppenheimer | Outperform |
| 2022-12-19 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-19 | 재확인 | Piper Sandler | Overweight |
| 2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-11-24 | 재개 | Evercore ISI | Outperform |
| 2020-11-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-01-30 | 개시 | Canaccord Genuity | Buy |
| 2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
| 2019-11-07 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-12-12 | 개시 | B. Riley FBR | Neutral |
| 2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 개시 | Citigroup | Buy |
| 2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
(MDGL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 30% Upside Beckons in the Biotech Sector - DirectorsTalk Interviews
Insider Sell: Richard Levy Sells Shares of Madrigal Pharmaceuticals Inc (MDGL) - GuruFocus
Director Richard Levy of Madrigal (MDGL) sells 5,682 shares under plan - Stock Titan
[144] MADRIGAL PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Madrigal Pharmaceuticals Inc (FRA:YDO1) Stock Price & 30 Year Financial Data - GuruFocus
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal hires 15 staff, grants 5,308 stock units vesting over 4 years - Stock Titan
Madrigal to present Rezdiffra data at EASL Congress 2026 - Investing.com UK
Madrigal to present Rezdiffra data at EASL Congress 2026 By Investing.com - Investing.com South Africa
Liver disease drug Rezdiffra shows new data on heart risk markers - Stock Titan
Madrigal (NASDAQ: MDGL) CMO has 844 shares sold automatically for tax withholding - Stock Titan
Insider sale notice: MDGL (NASDAQ: MDGL) 844 shares via Morgan Stanley - Stock Titan
Madrigal Pharmaceuticals (MDGL) Investor Outlook: Significant Potential Upside with a 28.77% Gain on the Horizon - DirectorsTalk Interviews
What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders - Sahm
Madrigal Pharmaceuticals Issues Equity Awards to 47 New Hires - MyChesCo
Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options - Sahm
Paulson & Co. (MDGL) holds 1.39M shares, representing 6.1% of Madrigal - Stock Titan
Madrigal Rezdiffra Sales More Than Double in First Quarter - MyChesCo
Janus Henderson (MDGL) discloses 2,018,647-share stake, 8.8% ownership - Stock Titan
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - MSN
Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum - MSN
Madrigal Licenses Arrowhead Drug Candidate for MASH - MyChesCo
Number of shareholders of Madrigal Pharmaceuticals, Inc. – GETTEX:YDO1 - TradingView
(MDGL) Risk Channels and Responsive Allocation - Stock Traders Daily
Madrigal’s (MDGL) MASH Strategy Reiinforced By Rezdiffra Sales Growth and Pipeline Expansion - MSN
Truist raises Madrigal Pharmaceuticals stock price target on MASH survey By Investing.com - Investing.com India
MDGL Maintained by Truist Securities -- Price Target Raised to $709 - GuruFocus
Madrigal Pharmaceuticals (NASDAQ:MDGL) Given New $709.00 Price Target at Truist Financial - MarketBeat
Truist raises Madrigal Pharmaceuticals stock price target on MASH survey - Investing.com
HC Wainwright Issues Pessimistic Estimate for MDGL Earnings - MarketBeat
HC Wainwright & Co. Maintains Madrigal Pharmaceuticals (MDGL) Buy Recommendation - MSN
TradingKey - TradingKey
West Conshohocken’s Madrigal Pharmaceuticals Eyes $1B Expansion Deal - VISTA.Today
Madrigal Pharmaceuticals expands MASH pipeline with genetic treatment - Liver Disease News
Madrigal Pharmaceuticals Q1 2026 Deep Dive: EPS Beats by 20.9%, Revenue Up 127% - AlphaStreet
Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Analyzing A 33% Upside Potential - DirectorsTalk Interviews
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales Growth - Yahoo Finance
Madrigal Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MDGL) 2026-05-09 - Seeking Alpha
Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $964 - Moomoo
Madrigal Pharmaceuticals (MDGL) Quarterly Loss Of US$94 Million Tests Bullish Margin Turnaround Narrative - Sahm
MDGL Maintained by Canaccord Genuity -- Price Target Lowered to $578 - GuruFocus
Madrigal (MDGL) Reports Strong Q1 Revenue and Positive Market Ou - GuruFocus
MDGL Maintains Rating by Evercore ISI Group -- Price Target Lowe - GuruFocus
47 new Madrigal hires get stock awards; options priced at $513.72 - Stock Titan
Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call - Sahm
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2026 Earnings Call Transcript - Insider Monkey
Madrigal Q1 2026 slides: blockbuster Rezdiffra tops $1.1B in sales - Investing.com Australia
Madrigal: Q1 Earnings Snapshot - theheraldreview.com
MSN Money - MSN
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):